Fenspiride
Clinical data | |
---|---|
Trade names | Eurespal, Pneumorel |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 90%[1] |
Elimination half-life | 14–16 hours |
Excretion | Urine (90%), feces (~10%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
KEGG | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C15H20N2O2 |
Molar mass | 260.331 g/mol |
(what is this?) (verify) |
WikiDoc Resources for Fenspiride |
Articles |
---|
Most recent articles on Fenspiride |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Fenspiride at Clinical Trials.gov Clinical Trials on Fenspiride at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Fenspiride
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Fenspiride Discussion groups on Fenspiride Patient Handouts on Fenspiride Directions to Hospitals Treating Fenspiride Risk calculators and risk factors for Fenspiride
|
Healthcare Provider Resources |
Causes & Risk Factors for Fenspiride |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Fenspiride (INN, brand names Eurespal, Pneumorel and others) is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases.[2] The pharmacotherapeutic classification is antitussives. In Russia it is approved for the treatment of acute and chronic inflammatory diseases of ENT organs (ear, nose, throat) and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as for maintenance treatment of asthma.[3]
Synthesis
The cyanohydrin of N-benzyl-4-piperidone is reduced with hydride to the aminoalcohol. This forms a cyclic carbamate on heating with diethyl carbonate. Hydrogenolysis of the N-benzyl group and alkylation of the liberated amino group with phenethyl chloride gives fenspiride.[4]
References
- ↑ Montes, B; Catalan, M; Roces, A; Jeanniot, JP; Honorato, JM (1993). "Single dose pharmacokinetics of fenspiride hydrochloride: phase I clinical trial". European journal of clinical pharmacology. 45 (2): 169–72. doi:10.1007/bf00315501. PMID 7901024.
- ↑ Płusa T, Nawacka D (Dec 1998). "Efficacy and tolerance of fenspiride in adult patients with acute respiratory tract infections". Pol Merkur Lekarski. 5 (30): 368–71. PMID 10101527.
- ↑ "Эреспал® (Eurespal®) Prescribing Information. VIDAL Drug Compendium" (in Russian). Retrieved 6 February 2014.
- ↑ NL 6504602
- Pages with script errors
- CS1 maint: Unrecognized language
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- Articles with changed DrugBank identifier
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical pages without ChemSpiderID
- Articles without InChI source
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Bronchodilators
- Drug